Your browser doesn't support javascript.
loading
Major milestones in translational oncology.
Dragani, Tommaso A; Castells, Antoni; Kulasingam, Vathany; Diamandis, Eleftherios P; Earl, Helena; Iams, Wade T; Lovly, Christine M; Sedelaar, J P Michiel; Schalken, Jack A.
Afiliação
  • Dragani TA; Fondazione IRCCS Istituto Nazionale dei Tumori, Via G.A. Amadeo 42, I-20133, Milan, Italy. tommaso.dragani@istitutotumori.mi.it.
  • Castells A; Department of Gastroenterology, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERehd, Barcelona, Catalonia, Spain.
  • Kulasingam V; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
  • Diamandis EP; Department of Clinical Biochemistry, University Health Network, Toronto, Ontario, Canada.
  • Earl H; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
  • Iams WT; Department of Clinical Biochemistry, University Health Network, Toronto, Ontario, Canada.
  • Lovly CM; Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Sedelaar JP; Deptartment of Oncology, University of Cambridge, Cambridge, UK.
  • Schalken JA; NIHR Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.
BMC Med ; 14(1): 110, 2016 07 28.
Article em En | MEDLINE | ID: mdl-27469586
ABSTRACT
Translational oncology represents a bridge between basic research and clinical practice in cancer medicine. Today, translational research in oncology benefits from an abundance of knowledge resulting from genome-scale studies regarding the molecular pathways involved in tumorigenesis. In this Forum article, we highlight the state of the art of translational oncology in five major cancer types. We illustrate the use of molecular profiling to subtype colorectal cancer for both diagnosis and treatment, and summarize the results of a nationwide screening program for ovarian cancer based on detection of a tumor biomarker in serum. Additionally, we discuss how circulating tumor DNA can be assayed to safely monitor breast cancer over the course of treatment, and report on how therapy with immune checkpoint inhibitors is proving effective in advanced lung cancer. Finally, we summarize efforts to use molecular profiling of prostate cancer biopsy specimens to support treatment decisions. Despite encouraging early successes, we cannot disregard the complex genetics of individual susceptibility to cancer nor the enormous complexity of the somatic changes observed in tumors, which urge particular attention to the development of personalized therapies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Biomarcadores Tumorais / Pesquisa Translacional Biomédica / Oncologia Tipo de estudo: Prognostic_studies / Screening_studies Limite: Humans Idioma: En Revista: BMC Med Assunto da revista: MEDICINA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Biomarcadores Tumorais / Pesquisa Translacional Biomédica / Oncologia Tipo de estudo: Prognostic_studies / Screening_studies Limite: Humans Idioma: En Revista: BMC Med Assunto da revista: MEDICINA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Itália